Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI ranks Organogenesis Holdings Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Organogenesis Holdings Inc. is a small-cap company with a market capitalization of $129M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its P/B Ratio of 0.87x is the lowest of the 42 peers that report one.
For ORGO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 33.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 16.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ORGO included.
Follow ORGO free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
| Metric | ORGO | Rank |
|---|---|---|
| Market Cap | $129M | 60/60 |
| P/B Ratio | 0.87x | 42/42 |
| EPS | $-0.52 | – |
| Book Value/Share | $1.15 | – |
| Revenue/Share | $3.56 | – |
| FCF/Share | $0.16 | – |
| Metric | ORGO | Rank |
|---|---|---|
| ROE | -56.8% | 29/38 |
| ROA | -20.7% | 32/43 |
| ROIC | -10.3% | 28/46 |
| Gross Margin | 75.8% | 22/36 |
| Operating Margin | -7.8% | 27/39 |
| Net Margin | -18.4% | 25/35 |
| EBT Margin | -7.6% | 33/46 |
| Tax Rate | -142.1% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
| Metric | ORGO | Rank |
|---|---|---|
| Current Ratio | 3.52x | 23/59 |
| Quick Ratio | 3.00x | 12/44 |
| D/E Ratio | 0.80x | 30/48 |
| Financial Leverage | 2.74x | 14/48 |
| Interest Coverage | 11.8x | 11/36 |
| Working Capital | $143M | 51/59 |
| Metric | ORGO | Rank |
|---|---|---|
| Operating Cash Flow | $32M | 35/59 |
| Free Cash Flow | $21M | 30/50 |
| Capital Spending | -$11M | 20/50 |
| FCF/Sales | 4.6% | 28/42 |
| CapEx/Sales | 2.4% | 25/42 |
| Metric | ORGO | Rank |
|---|---|---|
| Asset Turnover | 1.13x | 6/40 |
| Receivables Turnover | 4.5x | 26/38 |
| Inventory Turnover | 3.8x | 9/36 |
| Fixed Assets Turnover | 4.5x | 25/41 |
| Days Sales Outstanding | 81 days | 13/38 |
| Days Inventory | 96 days | 28/36 |
| Payables Period | 97 days | 19/26 |
| Cash Conversion Cycle | 80 days | 16/24 |
| Metric | ORGO | Rank |
|---|---|---|
| Total Revenue | $457M | 40/46 |
| Operating Income | -$36M | 29/51 |
| Net Income | -$84M | 28/46 |
| R&D Expense | $57M | 56/58 |
| SG&A Expense | $299M | 38/41 |
| Cost of Goods Sold | $111M | 30/37 |
| Metric | ORGO | Rank |
|---|---|---|
| Shares Outstanding | 129M | – |
| EPS Growth | -2700.0% | 25/25 |
| Total Current Assets | $200M | 49.3% of assets |
| Cash & Short-term Investments | $46M | 11.3% of assets |
| Accounts Receivable | $101M | 24.8% of assets |
| Inventory | $29M | 7.2% of assets |
| Total Liabilities | $118M | 29.1% of assets |
| Short-term Debt | $28M | 6.8% of assets |
Companies classified under the same SEC industry code as Organogenesis Holdings Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| ORGO Organogenesis Holdings Inc. | ▲ | $129M |
| LLY Eli Lilly & Co | ▶ | $1.18T |
| JNJ Johnson & Johnson | ▼ | $615.87B |
| ABBV Abbvie Inc. | ▶ | $504.37B |
| MRK Merck & Co., Inc. | ▲ | $360.08B |
| NVS Novartis Ag | ▼ | $287.41B |
| AZN Astrazeneca Plc | ▼ | $256.39B |
| ABT Abbott Laboratories | ▼ | $182.39B |
| NVO Novo Nordisk A S | ▼ | $172.56B |
| PFE Pfizer Inc | ▶ | $168.60B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▶ | $126.66B |
| BMY Bristol Myers Squibb Co | ▶ | $122.05B |
| GSK Gsk Plc | ▼ | $100.46B |
| SNY Sanofi | ▼ | $100.12B |
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $81.76B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $61.45B |
| TEVA Teva Pharmaceutical Industries Ltd | ▼ | $48.36B |
| ONC Beone Medicines Ltd. | ▲ | $41.96B |
| ZTS Zoetis Inc. | ▼ | $32.80B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $31.02B |
| RPRX Royalty Pharma Plc | ▶ | $26.88B |
| ROIV Roivant Sciences Ltd. | ▲ | $24.22B |
| GMAB Genmab A/S | ▲ | $23.80B |
| UTHR United Therapeutics Corp | ▶ | $22.87B |
| VTRS Viatris Inc | ▼ | $21.43B |
| INSM Insmed Inc | ▶ | $21.02B |
| ASND Ascendis Pharma A/S | ▲ | $14.85B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.65B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.98B |
| CORT Corcept Therapeutics Inc | ▲ | $11.91B |
| ELAN Elanco Animal Health Inc | ▼ | $11.77B |
| SMMT Summit Therapeutics Inc. | ▶ | $11.67B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.91B |
| BMRN Biomarin Pharmaceutical Inc | ▶ | $10.58B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.39B |
| CYTK Cytokinetics Inc | ▲ | $8.61B |
| TGTX Tg Therapeutics, Inc. | ▲ | $8.56B |
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.33B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.23B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $7.90B |
| ABVX Abivax S.A. | ▼ | $7.74B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.14B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.05B |
| ALKS Alkermes Plc. | ▲ | $6.92B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.75B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▶ | $6.13B |
| AMRX Amneal Pharmaceuticals, Inc. | ▲ | $6.13B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▲ | $5.93B |
| LGND Ligand Pharmaceuticals Inc | ▶ | $5.89B |
| BLTE Belite Bio, Inc | ▲ | $5.62B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.20B |
| COGT Cogent Biosciences, Inc. | ▶ | $5.12B |
| PTCT Ptc Therapeutics, Inc. | ▲ | $4.94B |
| ORKA Oruka Therapeutics, Inc. | ▲ | $4.76B |
| ERAS Erasca, Inc. | ▲ | $4.68B |
| MANE Veradermics, Inc | ▲ | $4.55B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.44B |
| EWTX Edgewise Therapeutics, Inc. | ▲ | $4.04B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.03B |
| INDV Indivior Pharmaceuticals, Inc. | ▶ | $3.83B |
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced ...
Welcome, ladies and gentlemen, to the Third Quarter 2025 Earnings Conference Call of Organogenesis Holdings, Inc. [Operator Instructions] Please note that this conference call is being recorded and ...
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products ...
Our AI ranks Organogenesis Holdings Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
For ORGO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 33.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 16.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Organogenesis Holdings Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
60 issuers in our coverage, ORGO included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.